Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Study of Envafolimab Plus Docetaxel in Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC Previously Treated With a PD-1 Inhibitor Combined With Chemotherapy

NCT05910034 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05910034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05910034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Study of Envafolimab Plus Docetaxel in Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC Previously Treated With a PD-1 Inhibitor Combined With Chemotherapy
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2023
Completion date
June 30, 2026
Enrollment
132 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer